Comparison of the effects of low-dose rosuvastatin on plasma levels of cholesterol and oxidized low-density lipoprotein in 3 ultracentrifugally separated low-density lipoprotein subfractions

Koichiro Honma, Yasuhiko Homma, Hideki Ozawa, Yutaka Shiina, Takeo Shibata, Tadashi Yoshida, Kazuhiro Hasegawa, Takeshi Kanda, Hirobumi Tokuyama, Shu Wakino, Koichi Hayashi, Hiroshi Itoh, Shingo Hori

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Plasma-oxidized (ox) low-density lipoprotein (LDL) is an atherogenic lipoprotein. The distribution of ox-LDL in plasma LDL subfractions and the effect of statins on this distribution have not been investigated in detail. Objective We examined the distribution of cholesterol and ox-LDL in 3 ultracentrifugally separated plasma LDL subfractions and investigated the effects of a statin, rosuvastatin, on the levels of these lipoproteins. Materials and methods Thirty-one polygenic hypercholesterolemic subjects were included in this study. Levels of cholesterol and ox-LDL in 3 plasma LDL subfractions and plasma levels of remnant-like particle cholesterol, ox-LDL, and adiponectin were measured after 0, 3, 6, and 12 months of treatment with rosuvastatin. Sequential ultracentrifugation was performed to subfractionate plasma lipoproteins. Results The mean daily dose of rosuvastatin over the 12 months of treatment was 2.9 ± 1.0 mg (mean ± standard deviation). The cholesterol subfraction distribution was 43 ± 10% as low-density LDL, 46 ± 8% as medium-density LDL, and 13 ± 5% as high-density LDL. Similarly, the distribution of ox-LDL was 31 ± 10% as low-density LDL, 48 ± 7% as medium-density LDL, and 22 ± 8% as high-density LDL. After 12 months of treatment with rosuvastatin, the level of cholesterol was significantly reduced in all 3 subfractions (P <.0001), as was the level of ox-LDL (P <.0001). Furthermore, the plasma cholesterol level in high-density lipoprotein2 increased significantly. Conclusions The distribution of ox-LDL in plasma LDL subfractions was more skewed toward the denser subfractions, compared with cholesterol. Rosuvastatin treatment significantly reduced plasma levels of cholesterol and ox-LDL in all LDL subfractions.

Original languageEnglish
Pages (from-to)751-757
Number of pages7
JournalJournal of Clinical Lipidology
Volume9
Issue number6
DOIs
Publication statusPublished - 2015 Nov 1

Keywords

  • Adiponectin
  • Carotid atherosclerosis
  • Cholesterol
  • hs-CRP
  • LDL subfractions
  • Oxidized LDL
  • Rosuvastatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Fingerprint Dive into the research topics of 'Comparison of the effects of low-dose rosuvastatin on plasma levels of cholesterol and oxidized low-density lipoprotein in 3 ultracentrifugally separated low-density lipoprotein subfractions'. Together they form a unique fingerprint.

  • Cite this